שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - amlodipinum, valsartanum - compresse rivestite con film - amlodipinum 10 mg ut amlodipini besilas, valsartanum 160 mg, cellulosum microcristallinum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, Überzug: hypromellosum, macrogolum 8000, talcum, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), vanillinum, pro compresso obducto. - essenziale ipertonia - synthetika

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - clozapinum - compresse - clozapinum 25.000 mg, lactosum monohydricum 48.000 mg, maydis amylum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, talcum, pro compresso. - neurolepticum - synthetika

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - clozapinum - compresse - clozapinum 100 mg, lactosum monohydricum 192 mg, maydis amylum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, talcum, pro compresso. - neurolepticum - synthetika

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - fingolimodum - capsule rigide - fingolimodum 0.5 mg ut fingolimodi hydrochloridum, calcii hydrogenophosphas dihydricus, glycinum, silica colloidalis anhydrica, magnesii stearas, kapselhülle: e 171, gelatina, e 172 (rubrum), e 172 (flavum), drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula. - multiple sklerose - synthetika

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - amlodipinum, valsartanum, hydrochlorothiazidum - compresse rivestite con film - filmtablette: amlodipinum 5 mg ut amlodipini besilas 6.944 mg, valsartanum 160 mg, hydrochlorothiazidum 12.5 mg, cellulosum microcristallinum, crospovidonum, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 4000, talcum, e 171, pro compresso obducto. - essenziale ipertonia - synthetika

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - amlodipinum, valsartanum, hydrochlorothiazidum - compresse rivestite con film - filmtablette: amlodipinum 10 mg ut amlodipini besilas 13.888 mg, valsartanum 160 mg, hydrochlorothiazidum 12.5 mg, cellulosum microcristallinum, crospovidonum, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 4000, talcum, e 171, e 172 (flavum), e 172 (rubrum), pro compresso obducto. - essenziale ipertonia - synthetika

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - amlodipinum, valsartanum, hydrochlorothiazidum - compresse rivestite con film - filmtablette: amlodipinum 5 mg ut amlodipini besilas 6.944 mg, valsartanum 160 mg, hydrochlorothiazidum 25 mg, cellulosum microcristallinum, crospovidonum, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 4000, talcum, e 171, e 172 (flavum), pro compresso obducto. - essenziale ipertonia - synthetika

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - amlodipinum, valsartanum, hydrochlorothiazidum - compresse rivestite con film - filmtablette: amlodipinum 10 mg ut amlodipini besilas 13.888 mg, valsartanum 160 mg, hydrochlorothiazidum 25 mg, cellulosum microcristallinum, crospovidonum, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 4000, talcum, e 171, e 172 (flavum), pro compresso obducto. - essenziale ipertonia - synthetika

האיחוד האירופי - איטלקית - EMA (European Medicines Agency)

mylan ire healthcare limited - sodio fondaparinux - venous thrombosis; pulmonary embolism; myocardial infarction; angina, unstable - agenti antitrombotici - 5 mg / 0. 3 ml e 2. 5 mg / 0. 5-ml solution for injectionprevention of venous thromboembolic events (vte) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery. la prevenzione del tev in adulti sottoposti a chirurgia addominale considerati ad alto rischio di complicanze tromboemboliche, quali pazienti sottoposti a chirurgia addominale per patologie tumorali. la prevenzione del tev in adulti medica i pazienti che sono considerati ad alto rischio di tev e che sono immobilizzati a causa di una malattia acuta, ad esempio insufficienza cardiaca e / o respiratoria acuta disturbi e / o infettive acute o di malattia infiammatoria. il trattamento di adulti con acuta sintomatica spontanea superficiale-trombosi venosa profonda degli arti inferiori, senza somministrazione concomitante di trombosi venosa profonda. 5 mg / 0. 5-ml solution for injectiontreatment of unstable angina or non-st-segment-elevation myocardial infarction (ua/nstemi) in adult patients for whom urgent (< 120 mins) invasive management (pci) is not indicated. miocardico acuto (stemi) in pazienti adulti che non sono gestiti con trombolitici o che sono inizialmente per ricevere nessuna altra forma di terapia di riperfusione. 5 mg / 0. 4-ml, 7. 5 mg / 0. da 6 ml e 10 mg/0. 8-ml solution for injectiontreatment of adults with acute deep-vein thrombosis (dvt) and treatment of acute pulmonary embolism (pe), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.

איטליה - איטלקית - AIFA (Agenzia Italiana del Farmaco)

viatris healthcare limited - clortetraciclina - clortetraciclina